TY - JOUR
T1 - Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions
AU - Fam, Jiang Ming
AU - Ojeda, Soledad
AU - Garbo, Roberto
AU - Latib, Azeem
AU - La Manna, Alessio
AU - Vaquerizo, Beatriz
AU - Boukhris, Marouane
AU - Vlachojannis, Georgios J.
AU - Van Geuns, Robert Jan
AU - Ezhumalai, Babu
AU - Kawamoto, Hiroyoshi
AU - Van Der Sijde, Jors
AU - Felix, Cordula
AU - Pan, Manuel
AU - Serdoz, Roberta
AU - Boccuzzi, Giacomo Giovanni
AU - De Paolis, Marcella
AU - Sardella, Gennaro
AU - Mancone, Massimo
AU - Tamburino, Corrado
AU - Smits, Pieter C.
AU - Di Mario, Carlo
AU - Seth, Ashok
AU - Serra, Antonio
AU - Colombo, Antonio
AU - Serruys, Patrick
AU - Galassi, Alfredo R.
AU - Zijlstra, Felix
AU - Van Mieghem, Nicolas M.
AU - Diletti, Roberto
AU - Thiele, Holger
N1 - Publisher Copyright:
© Europa Digital & Publishing 2017. All rights reserved.
PY - 2017/6
Y1 - 2017/6
N2 - Aims: Bioresorbable vascular scaffolds (BVS) represent a novel therapeutic option for the treatment of coronary artery diseases. The objective of this study was to evaluate the feasibility of BVS implantation in complex chronic total occlusions (CTO). Methods and results: The present report is a multicentre registry evaluating results after BVS deployment in challenging CTO lesions, defined as J-CTO score ≥2 (difficult or very difficult). A total of 105 patients were included in the present analysis. The mean J-CTO score was 2.61 (difficult 52.4%, very difficult 47.6%). Device success and procedural success rates were 98.1% and 97.1%, respectively. The retrograde approach was used in 25.7% of cases. After wire crossing, predilatation was performed in all cases with a mean predilatation balloon diameter of 2.73±0.43 mm. The mean scaffold length was 59.75±25.85 mm, with post-dilatation performed in 89.5% of the cases and a mean post-dilatation balloon diameter of 3.35±0.44 mm. Post-PCI minimal lumen diameter was 2.50±0.51 mm and percentage diameter stenosis 14.53±10.31%. At six-month follow-up, a total of three events were reported: one periprocedural myocardial infarction, one late scaffold thrombosis and one additional target lesion revascularisation. Conclusions: The present report suggests the feasibility of BVS implantation in complex CTO lesions, given adequate lesion preparation and post-dilatation, with good acute angiographic results and midterm clinical outcomes.
AB - Aims: Bioresorbable vascular scaffolds (BVS) represent a novel therapeutic option for the treatment of coronary artery diseases. The objective of this study was to evaluate the feasibility of BVS implantation in complex chronic total occlusions (CTO). Methods and results: The present report is a multicentre registry evaluating results after BVS deployment in challenging CTO lesions, defined as J-CTO score ≥2 (difficult or very difficult). A total of 105 patients were included in the present analysis. The mean J-CTO score was 2.61 (difficult 52.4%, very difficult 47.6%). Device success and procedural success rates were 98.1% and 97.1%, respectively. The retrograde approach was used in 25.7% of cases. After wire crossing, predilatation was performed in all cases with a mean predilatation balloon diameter of 2.73±0.43 mm. The mean scaffold length was 59.75±25.85 mm, with post-dilatation performed in 89.5% of the cases and a mean post-dilatation balloon diameter of 3.35±0.44 mm. Post-PCI minimal lumen diameter was 2.50±0.51 mm and percentage diameter stenosis 14.53±10.31%. At six-month follow-up, a total of three events were reported: one periprocedural myocardial infarction, one late scaffold thrombosis and one additional target lesion revascularisation. Conclusions: The present report suggests the feasibility of BVS implantation in complex CTO lesions, given adequate lesion preparation and post-dilatation, with good acute angiographic results and midterm clinical outcomes.
KW - Bioresorbable scaffolds
KW - Chronic coronary total occlusion
KW - Stable angina
UR - http://www.scopus.com/inward/record.url?scp=85021067051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021067051&partnerID=8YFLogxK
U2 - 10.4244/EIJ-D-16-00253
DO - 10.4244/EIJ-D-16-00253
M3 - Article
C2 - 28218604
AN - SCOPUS:85021067051
SN - 1774-024X
VL - 13
SP - 355
EP - 363
JO - EuroIntervention
JF - EuroIntervention
IS - 3
ER -